
[ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . CONFIDENTIAL

EXECUTION VERSION

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this "Agreement")  dated  as of  May 31, 2017  (the "Effective  Date  "), is  made  and  entered  into by and between Array BioPharma Inc., a company  organized  under the laws of Delaware and  having  its principal place of business at 3200 Walnut Street, Boulder, CO 80301 USA, ("Array") and Ono Pharmaceutical Co., Ltd., a company duly  organized  and  existing  under the laws of Japan,  having  offices and principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan ("Ono"). BACKGROUND

A. Array  now   owns  or  controls  certain patents,  know  -how and other intellectual property  relating  to the Products (as  defined  below);

B. Ono has experience in developing, marketing and  distributing  pharmaceutical products;

C. Array and Ono  wish  to  collaborate  on the further development, manufacture and commercialization of the Products, with Ono  taking  the lead role in such efforts in the Ono Territory (as  defined  below); and

D. Array is willing to  grant  to Ono, and Ono desires to  obtain  , certain exclusive rights and licenses with respect to the manufacture, registration and commercialization of the Products in the Ono Territory. Array will  retain  the right to  develop  and  commercialize  the Products for the Array Territory, all on the terms and conditions set forth herein. NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein  contained  , and for other good and valuable consideration, the receipt and sufficiency of which are hereby  acknowledged  , the Parties hereby  agree  as  follows  :

ARTICLE I   DEFINITIONS

1.1 "Affiliate" of a Party means any person, corporation or other entity that, directly or indirectly, controls, is controlled by, or is under common control with such Party, as the case may be. As  used  in this Section 1.1, the word "control" ( including  , with correlative meaning, the terms "controlled by" or "under the common control with") shall mean the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting share capital in such person, corporation, or other entity, or by contract or otherwise. 1.2 "Annual Net Sales" means the Net Sales generated over any given Fiscal Year, or in the case of the Fiscal Year in which the First Commercial Sale of the first Product occurs, the Net Sales generated during the period commencing on the date of such First Commercial Sale and continuing until the end of such Fiscal Year. [ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . 1.3 "Applicable Regulatory Exclusivity Period" means with respect to a particular Product and particular country in the Ono Territory, the period commencing upon the receipt of the first grant of Regulatory Exclusivity in such country for such Product ("Initial Regulatory Exclusivity"), and continuing until the later of (i) the expiration of such Initial Regulatory Exclusivity, or (ii) if any subsequent grant of Regulatory Exclusivity is received prior the expiration of the Initial Regulatory Exclusivity, then until the expiration of such additional Regulatory Exclusivity if such expiration would occur after the expiration of the Initial Regulatory Exclusivity. 1.4 "Array Know-How" means, subject to Section 4.4(c)(ii), all scientific, medical, technical, manufacturing, marketing, regulatory, market access and other information (including clinical data and other related information generated in compliance with CDISC standards) relating to Binimetinib, Encorafinib, a Product and/or any Companion Diagnostic useful with respect to the Development, Manufacturing, registration (including registration for MAA) or Commercialization of a Product (including the Data), to the extent Controlled by Array or its Controlled Affiliates as of the Effective  Date  or during the  term  of this Agreement, and needed by or reasonably useful to Ono in order for Ono to exercise its rights or perform its obligations under this Agreement. Notwithstanding the foregoing or Section 1.18 (Data) below, but subject to Section 2.4 (Future Third Party Partners), Array Know-How shall in any case  include  all such items that are  generated  by or under authority of Array, or any of its Affiliates, in connection with Development Manufacturing, and/or Commercialization of the Product during the  term  of this Agreement. 1.5 "Array Patents" means the Patents Controlled by Array or its Controlled Affiliates as of the Effective  Date  or during the  term  of this Agreement that:

(a)  are  listed  on Exhibit 1.5; or

(b) but for the license  granted  under this Agreement, would be  infringed  by the Development, Manufacturing, registration, packaging, or Commercialization of a Product in the Ono Territory ( including  the identification of patients who would  benefit  from the Product  based  on the presence or absence of  selected  biomarkers); and

(c)  all additions, divisions, continuations, substitutions, re-issues, re-examinations, registrations, patent  term  extensions, supplemental protection certificates, and renewals of any the Patents  listed  on Exhibit 1.5 or to the extent the same would  satisfy  the requirements of subsection (b) above. 1.1 "Array Territory" means all countries worldwide, excluding the Ono Territory. 2







[ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . 1.2 "Binimetinib" means the compound known as MEK162, the chemical structure of which is depicted in Exhibit 1.7 as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph or radiolabeled equivalent thereof. 1.3 "Business Days" means any  day  other than  Saturday ,  Sunday ,  a day  within Array's company-wide corporate holidays (for Array's obligations) or Ono's company-wide corporate holidays (for Ono's obligations) or any other  day  on which commercial banks in USA or Japan are authorized or required by law to remain closed. 1.4 "Calendar Year" means any period of time commencing on  January 1  and ending on  the next December 31  unless otherwise noted. 1.5 "CDISC" means Clinical Data Interchange Standards Consortium which is an interdisciplinary nonprofit organization that establishes international standards for data collection, interchange, application, and storage for the purpose of promoting interoperation of clinical research data. 1.6 "Change in Control" means, with respect to a Party, that any of the following occurs with respect to such Party after the Effective  Date  :

(a)  any "person" or "group" (as such terms are  defined  below) (i) is or  becomes  the "beneficial owner" (as  defined  below, except that a "person" or "group" shall be  deemed  to have "beneficial ownership" of all shares of capital stock or other equity interests if such person or group has the right to  acquire  , whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of shares of capital stock or other interests ( including  partnership interests) of such Party then outstanding and normally  entitled  (without regard to the occurrence of any contingency) to  vote  in the election of the directors, managers or similar supervisory positions ("Voting Stock") of such Party  representing  more than fifty percent (50%) of the total  voting  power of all outstanding classes of Voting Stock of such Party or (ii) has the power, directly or indirectly, to  elect  a majority of the members of such Party's board of directors or similar governing body;

(b) such Party  enters  into a merger, consolidation or similar transaction with another Person (whether or not such Party is the  surviving  entity) and as a result of such merger, consolidation or similar transaction the Persons that beneficially  owned  , directly or indirectly, the shares of Voting Stock of such Party immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party  representing  at least a majority of the total  voting  power of all outstanding classes of Voting Stock of the  surviving  Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such transaction; or

3







[ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . (c)  such Party  sells  or transfers to any Third Party, in one or more related transactions, properties or assets  representing  all or substantially all of such Party's assets to which this Agreement  relates  . For the purpose of this definition of Change in Control: (i) "person" and "group" have the meanings  given  such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of  1934  and the  term  "group"  includes  any group  acting  for the purpose of  acquiring  ,  holding  or disposing of securities within the meaning of Rule 13d-5(b)(1) under the aforesaid Act; (ii) a "beneficial owner" shall be determined in accordance with Rule 13d-3 under the aforesaid Act; (iii) the terms "beneficially owned" and "beneficially own" shall have meanings correlative to that of "beneficial owner"; and (iv)"Person" means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity or any government, any agency or political subdivisions thereof. Such "person" or "group" in Section 1.11(a), such  surviving  Person in Section 1.11(b) or such Third Party in Section 1.11(c) shall be  referred  to herein as "Acquirer". 1.7 "Clinical Studies" means any human clinical study of a Product, including without limitation Post-Approval Marketing Clinical Studies. 1.8 "Combination Product" means any pharmaceutical preparations, in any dosage strengths, formulations and methods of administration, that combine Binimetinib or Encorafenib and one or more other active ingredients (other than Binimetinib or Encorafenib) in fixed dose combination, whether co-formulated or co-packaged. 1.9 "Commercialization" means all processes and activities conducted to establish and maintain sales for the Products, including offering for sale, distribution, detailing, selling (including launch), promoting, importing, exporting, market access activities, all marketing activities undertaken prior to and after the launch of the Products (including education and advertising activities), branding, developing promotional materials, advertising, organizing speakers programs and post-marketing safety surveillance and reporting. "Commercialize" and "Commercializing" shall have the correlative meanings. 1.10 "Companion Diagnostic" means an in vitro diagnostic medical device as defined in the European directive 98/79/EC; for the avoidance of doubt the  term  Companion Diagnostic includes companion diagnostics for a pharmaceutical product as defined in FDA's "Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Devices". 1.11 "Control" ( including  any variations such as "Controlled" and " Controlling  "), in the context of intellectual property rights, data and/or other information, means that such Party or its Affiliate owns, is licensed or otherwise possesses rights to such intellectual property, data and/or information,

4







[ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . as applicable, sufficient to  grant  the applicable license or sublicense under this Agreement, without  violating  the terms of an agreement with a Third Party in existence as of the time such Party or its Affiliates would first be  required  hereunder to  grant  the other Party such (sub)license, right to  use  or access. 1.12 "Controlled Affiliates" means, with respect to a Party, any Affiliate that is controlled (as defined in Section 1.1) by such Party. 1.13 "Data" means, subject to Section 1.51 (Ono Know-How) and Section 4.4(c)(ii), any and all research data, pharmacology data, preclinical data, clinical data and/or all Regulatory Filings and/or other regulatory documentation, information and submissions pertaining to, or made in association with an IND, Marketing Approval Application, Marketing Approval or Pricing and Reimbursement Approvals, or any Post-Approval Marketing Clinical Study for each Product, in each case to the extent Controlled by a Party or its Affiliates as of the Effective  Date  or during the  term  of this Agreement. 1.14  "Development" or " Develop  " means non-clinical and clinical research and drug development activities, including toxicology, pharmacology, statistical analysis, Clinical Studies (including pre- and post-approval studies, Post-Approval Marketing Clinical Studies and Investigator Sponsored Clinical Studies), stability testing, formulation, process development, quality assurance/control development, regulatory affairs, and regulatory activities pertaining to designing and carrying out Clinical Studies and obtaining and maintaining Marketing Approvals (including pre-marketing activities but excluding regulatory activities directed to obtaining Pricing and Reimbursement Approvals). 1.15 "Diligent Efforts" means, with respect to the efforts to be expended by a Party, with respect to any objective, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances for such Party's benefit. Without  limiting  the foregoing, with respect to efforts  relating  to the Development of,  obtaining  Marketing Approval or Pricing and Reimbursement Approval for, or Commercialization of the Product, generally or with respect to any particular country, "Diligent Efforts" means a sustained, continued and active commitment of efforts and resources by a Party consistent with those normally applied in the pharmaceutical industry with respect to compounds or products with similar market at a similar stage in the product life cycle that such Party is actively developing or commercializing (as applicable), taking into account the stage and risk of development or commercialization of the Product, issues of safety or efficacy, the cost effectiveness of efforts or resources while optimizing profitability, the competitiveness of alternative Third Party compounds, products or generics that are or are expected to be in the marketplace, the scope and duration of Patents or other intellectual property rights related to the compound or product (including any Regulatory Exclusivity), the profitability of the Product (including pricing and reimbursement status achieved or likely to be achieved) or other relevant commercial factors,

5







[ * ] = Certain confidential information  contained  in this document,  marked  by brackets, has been  omitted  and  filed  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  amended  . but not  taking  into account (a) any other pharmaceutical product such Party is then  researching  ,  developing  or commercializing, alone or with one or more collaborators, or (b) any payments  required  to be  made  to the other Party hereunder. 1.16 "EMA" means the European Medicines Agency, or any successor entity thereto performing similar functions. 1.17 "Encorafenib" means the compound known as LGX818, the chemical structure of which is depicted in Exhibit 1.22, as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph, or radiolabeled equivalent thereof. 1.18  "FDA" means the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions. 1.19 "Field" means the diagnosis, treatment and/or prevention of diseases and conditions in humans.
